Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

NEW HAVEN, Conn., March 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VIOND) today announced financial results for the fourth quarter and year-end of 2007.

The Company reported a net loss of $34.0 million, or $5.05 per share, for the year ended December 31, 2007, compared with a net loss of $25.3 million, or $3.83 per share, for 2006. Weighted-average common shares outstanding for the years ended December 31, 2007 and December 31, 2006 were 6.7 million and 6.6 million, respectively. The net loss increased in 2007 by $8.7 million over the previous year, primarily as a result of non-cash expenses including: (i) $5.1 million of interest expense related to Vion's convertible senior notes and (ii) $2.5 million of higher stock-based compensation expense. In addition, costs associated with clinical, regulatory and pre-commercialization activities for the Company's lead product candidate, Cloretazine(R) (VNP40101M) increased year-over-year.

The Company reported ending the year with $61.1 million in cash and cash equivalents.

Alan Kessman, Chief Executive Officer, commented, "Based on our current operating plan, we are funded through the third quarter of 2009. We continue to make progress on preparing a New Drug Application for our lead anticancer agent Cloretazine(R) (VNP40101M) for filing with the U.S. Food and Drug Administration in 2008."

A net loss of $8.2 million, or $1.18 per share, was reported for the fourth quarter of 2007, compared with a net loss of $6.1 million, or $0.92 per share, for the same period in 2006. Weighted-average common shares outstanding for the three months ended December 31, 2007 and 2006 were 6.9 million and 6.6 million, respectively.

On February 20, 2008, the Co
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... WI (PRWEB) April 25, 2015 Join ... April 29th: Analyzing Kinase Inhibitor Residence Times using the ... Analysis of inhibitor residence times is increasingly being incorporated ... target can result in improved efficacy, increased therapeutic window ... be determined using immobilized ligand methods such surface plasmon ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Top student ... other San Diego area universities, including UCSD and SDSU, ... judges from prominent local, national and nonprofit companies for ... the 5th Annual Social Innovation Challenge 2015 . ... unique social venture ideas addressing a diverse range of ...
(Date:4/24/2015)... SD and Tempe, AZ (PRWEB) April 24, 2015 ... Technology and Arizona State University (ASU) have entered into ... joint projects. , A memorandum of agreement signed by ... long distance learning, student success and other services particularly, ... resources. , “We have complementary strengths and a ...
(Date:4/24/2015)... April 24, 2015 Leading Regenerative ... in its allogeneic stem-cell product development program and ... reflect the corporate strategic direction. , “I am ... adipose stem cell development program has been kicked ... cGMP manufacturing facility and hiring of our new ...
Breaking Biology Technology:BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2
... TRIANGLE PARK, N.C., Jan. 24 Quintiles,Transnational Corp. ... investor partnership to support the company,s continued,growth under ... CEO Dennis,Gillings, CBE, and the management team. Gillings ... Capital have become the lead,investors in Quintiles, with ...
... BOHEMIA, N.Y., Jan. 23 NBTY, Inc. (NYSE: NTY ... nutritional,supplements, today announced it will web cast a conference call ... http://www.nbty.com on,Monday, January 28, 2008 at 8:30 AM ... will be issued at 7:00 AM (ET) that,day., A ...
... PPD, Inc. (Nasdaq:,PPDI) today announced that it ... through an exclusive agreement with Peking Union Lawke,Biomedical ... begin,immediately providing biopharmaceutical clients with its full range ... "Chinese law makes it extremely difficult to export ...
Cached Biology Technology:Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3NBTY to Web Cast Fiscal First Quarter Conference Call 2PPD Expands Global Central Lab Services into China 2PPD Expands Global Central Lab Services into China 3
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... in stores or order in restaurants, the chance that an individual ... causes. This may seem obvious to most (they had to get ... that the relentless pursuit of consumer-friendly fish product is having a ... only the biggest fish, or only those found in certain habitats, ...
... to assessing risk for type 2 diabetes, not only do waistlines ... cells. This new discovery by a team of Swedish researchers ... and helps explain why some women of normal weight develop type ... knowledge of the link between enlarged fat cells and the development ...
... MONTREAL, CN (September 10, 2009) Recent research to ... constricts blood vessels and stimulates cell growth, has led ... hope for treating other chronic diseases. The usefulness of ... much less clear, said Professor Matthias Barton, M.D. of ...
Cached Biology News:Changing the course of nature: Are fisheries directing the evolution of fish populations? 2Size of fat cells and waist size predict type 2 diabetes in women 2Endothelin drugs benefit those with pulmonary hypertension 2Endothelin drugs benefit those with pulmonary hypertension 3
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
GOAT ANTI SLI...
Protein Phosphorylation...
ANTI L-DOPA...
Biology Products: